REVIVA PHARMACEUTICALS HOLDINGS, INC. 8-K

What Happened

• Reviva Pharmaceuticals Holdings, Inc. announced that the Nasdaq Hearings Panel granted the company an exception to demonstrate compliance with Nasdaq’s $1.00 minimum bid price listing requirement through March 27, 2026. The Panel decision was communicated on January 20, 2026 following a hearing held January 8, 2026.
• This Exception follows a Nasdaq notice dated May 13, 2025 that the company was not in compliance with Nasdaq Listing Rule 5550(a)(2). Reviva had a 180-calendar-day compliance period ending November 10, 2025 and received a Nasdaq letter on November 11, 2025 indicating a delisting determination unless a hearing was requested; Reviva timely requested the hearing.

Key Details

• Exception period end date: March 27, 2026 (Panel granted on Jan. 20, 2026 after Jan. 8 hearing).
• Compliance requirement: closing bid price must be at least $1.00 for a minimum of 10 consecutive business days (Panel may extend).
• Company actions: Reviva says it will monitor the bid price and may implement a reverse stock split if necessary to regain compliance.
• Nasdaq conditions: Reviva must promptly notify the Panel of any significant events during the Exception period; the Panel may reconsider the Exception if circumstances change.

Why It Matters

• For investors, the Exception temporarily preserves Reviva’s Nasdaq listing but sets a firm deadline to cure the $1.00 bid-price deficiency. Failure to meet the requirement could lead to delisting, which typically reduces liquidity, makes trading and accurate quotes harder to obtain, and can materially reduce the stock price and access to capital.
• The company’s mention of a possible reverse stock split is a common remedy but can itself affect share price, outstanding share count and liquidity. Reviva also updated its risk-factor disclosures to reflect these listing risks and the forward-looking uncertainties tied to Nasdaq’s process.